| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
134,986 |
251,929 |
319,053 |
656,089 |
| Total Sell Value |
$11,097,511 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
9 |
19 |
27 |
56 |
| End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Davis George Eric |
EVP, General Counsel |
• – – |
2016-06-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
120 |
72,836 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2016-06-16 |
4 |
AS |
$80.55 |
$3,356,196 |
D/D |
(41,666) |
378,584 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2016-06-16 |
4 |
OE |
$17.54 |
$730,822 |
D/D |
41,666 |
420,250 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-06-06 |
4 |
AS |
$89.14 |
$146,992 |
D/D |
(1,649) |
46,944 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,510 |
26,760 |
|
- |
|
| Slamon Dennis |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,510 |
7,835 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
760 |
2,860 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,510 |
24,010 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,510 |
14,410 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,510 |
37,135 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2016-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,510 |
27,760 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$147,960 |
D/D |
(1,644) |
128,742 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$133,920 |
D/D |
(1,488) |
59,809 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$183,240 |
D/D |
(2,036) |
113,878 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2016-06-03 |
4 |
D |
$90.00 |
$597,600 |
D/D |
(6,640) |
378,584 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$162,090 |
D/D |
(1,801) |
48,593 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$133,920 |
D/D |
(1,488) |
72,956 |
|
- |
|
| Mueller Brian |
VP, Corporate Controller |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$33,840 |
D/D |
(376) |
14,547 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-05-31 |
4 |
AS |
$89.35 |
$1,873,126 |
D/D |
(20,841) |
50,394 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-05-31 |
4 |
OE |
$39.06 |
$659,958 |
D/D |
16,896 |
71,235 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-05-27 |
4 |
D |
$89.09 |
$383,532 |
D/D |
(4,305) |
54,339 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2016-05-26 |
4 |
S |
$87.34 |
$1,317,100 |
D/D |
(15,000) |
115,914 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2016-05-26 |
4 |
OE |
$26.49 |
$397,350 |
D/D |
15,000 |
130,914 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-05-23 |
4 |
AS |
$87.07 |
$328,184 |
D/D |
(3,769) |
58,644 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2016-05-18 |
4 |
S |
$87.05 |
$435,249 |
D/D |
(5,000) |
130,386 |
|
- |
|
1285 Records found
|
|
Page 41 of 52 |
|
|
1.44 (1.6%) 
